CLAIMS

What is claimed is:

1. A crystalline form of (*S*, *E*)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide (ABT-101) free base characterized by an X-ray powder diffraction pattern comprising peaks at 2θ values of 4.8°±0.2° , 9.5°±0.2°, 10.2°±0.2°, 12.5°±0.2°, 15.0°±0.2°, 18.4°±0.2° and 20.8°±0.2°.
2. The crystalline form of claim 1, characterized by an X-ray powder diffraction pattern further comprising a peaks at 2θ value of 8.7°±0.2°.
3. The crystalline form of claim 1, characterized by an X-ray powder diffraction pattern further comprising a peak at 2θ value of 19.4°±0.2°.
4. The crystalline form of claim 1, characterized by an X-ray powder diffraction pattern further comprising a peak at 2θ value of 23.1°±0.2°.
5. The crystalline form of claim 1, having a melting point temperature of 170 to 195 ℃.
6. The crystalline form of claim 1, having an enthalpy of melting of 75 to 85 ℃.
7. A pharmaceutical composition comprising the crystalline form of claim 1, and a pharmaceutically acceptable carrier or excipient.
8. The pharmaceutical composition of claim 7, which is a EGFR inhibitor, a HER2 inhibitor or a tumor-agnostic inhibitor.
9. The pharmaceutical composition of claim 7, which is in a form of a capsule.
10. The pharmaceutical composition of claim 9, comprising from 0.1 to 200 mg of the crystalline form of claim 1.
11. The pharmaceutical composition of claim 9, comprising from 25 to 100 mg of the crystalline form of claim 1.
12. The pharmaceutical composition of claim 9, comprising from 50 to 100 mg of the crystalline form of claim 1.
13. The pharmaceutical composition of claim 9, wherein the pharmaceutically acceptable carrier or excipient comprises a filler.
14. The pharmaceutical composition of claim 9, wherein the pharmaceutically acceptable carrier or excipient comprises a disintegrant.
15. The pharmaceutical composition of claim 9, wherein the pharmaceutically acceptable

°

carrier or excipient comprises a lubricant.

16. Use of the crystalline form of any one of claims 1 to 6 in the manufacture of a medicament for the treatment of cancer.
17. The use of Claim 16, wherein the crystalline form of any one of claims 1 to 6 is a EGFR inhibitor, a HER2 inhibitor or a tumor-agnostic inhibitor.
18. The use of Claim 16, wherein the cancer is peritoneal cancer, small intestine cancer, non-small cell lung cancer (NSCLC), neuroendocrine cancer, salivary gland, bladder cancer, breast cancer, cervix cancer, bile duct cancer, esophageal cancer, stomach cancer, early gastric cancer, colorectal cancer, prostate cancer, ovarian cancer, head and neck cancer, endometrial cancer, kidney cancer, melanoma cancer, sarcoma cancer, pancreatic cancer, small cell lung cancer (SCLC), leukemia cancer, brain cancer or thyroid cancer.